Impel Neuropharma Inc.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2016 | $22 M | No. 5 | $10 to $50 million | equity | SEC | |
| Jul 2016 | $1 M | No. 4 | Under $2 million | debt, options | SEC | |
| Sep 2015 | $4 M | No. 3 | $2 to $10 million | equity, options | SEC | |
| Aug 2015 | $1 M | No. 2 | Under $2 million | equity | SEC | |
| Nov 2013 | $3 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Impel Neuropharma Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2016).
SEC Form D · Dec 2016
The industry group it chose in its notices: Other Health Care.
SEC Form D · Dec 2016
That is all the official record says: Impel Neuropharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
In its own words
How the company describes itself to search engines on its website, word for word.
“Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
19 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Partners V, LLC | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| 5AM Ventures V, L.P. | Venture capital | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| H. Stewart Parker | Person | not stated | not stated | Held Series A-2 and C-1 preferred stock, director (Form 3, 2021) | SEC Form 3 |
| John Hoekman | Person | not stated | not stated | Held Series A-2 preferred stock (Form 3, 2021) | SEC Form 3 |
| KKR Associates HCSG L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Fund Holdings L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Group Holdings Corp. | Company | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Hcsg GP LLC | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Healthcare Strategic Growth Fund L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Iris Investors LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| KKR Management LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Norwest Venture Partners XIV, LP | Venture capital | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| venBio Global Strategic Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| venBio Global Strategic GP II, L.P. | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| venBio Global Strategic GP II, Ltd. | Company | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital Surplus Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital VIII, LLC | Fund or asset manager | not stated | not stated | Held Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 21 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John D. Hoekman | Executive officer | Dec 2016 |
| Michael P. Hite | Executive officer | Sep 2015 |
| Aaron D. Royston | Director | Dec 2016 |
| Jim D. Young | Director | Dec 2016 |
| John D. Hoekman | Director | Dec 2016 |
| Mahendra D. Shah | Director | Dec 2016 |
| Stewart D. Parker | Director | Dec 2016 |
| Michael P. Hite | Director | Sep 2015 |
| Rodney D. Ho | Director | Nov 2013 |
About
Company in Seattle, United States.